You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Onyx ONE Global Trial results
Published by The New England Journal of Medicine
Evaluated 752 HBR patients in the U.S. and Japan from the single-arm analysis, pooled with similar Resolute Onyx DES patients from the Onyx ONE Global Trial who were clear of events after 1-month DAPT.
Onyx ONE Clear Analysis
Published by Circulation: Cardiovascular Interventions
See how Onyx ONE compares to XIENCE 28 and POEM trials when it comes to trial design and patient population.
Third-party brands are trademarks of their respective owners.
Resolute Onyx DES received CE mark approval for 1-month DAPT in HBR patients in 2020.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.
Windecker S, et al. Final Two-Year Results from the Randomized Onyx ONE Trial in High Bleeding Risk Patients Treated with 1-month DAPT. Presented at ACC 2021.
Kandzari DE, Kirtane AJ, Windecker S, et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv. November 2020;13(11):e009565.
Resolute Onyx DES IFU.